Comprehensive Molecular-Clinical Profiling of Cholangiocarcinoma According to Pathologic Subtypes
HPB · 2026
DOI: 10.1016/j.hpb.2026.02.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift HPB, 2026. Verfasst von Keun Soo Ahn und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Keimyung University School of Medicine, Dongsan Medical Center, Daegu, Republic of Korea. Electronic address: ahnks@dsmc.or.kr. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Mutation, Biomarkers, Tumor. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Korea Ministry of Education.
Abstract (Originalsprache)
BACKGROUND: Pathologically, cholangiocarcinoma (CCA) can be classified into small duct type and large duct type. This study evaluated clinical and molecular features of CCA according to its pathological subtype. METHODS: We analyzed 107 patients with CCA from three independent cohorts who underwent curative surgical resection. Clinical data, gene expression profiles, and mutation status were compared between pathological subtypes. RESULTS: Sixty four (59.8 %) and 43 (30.2 %) patients were categorized as small duct type and large duct type, respectively. The large duct type was significantly associated with N1 stage and higher preoperative serum CEA and CA 19-9 levels. Survival outcomes were significantly poorer in patients with large duct type CCA. Transcriptomic analysis identified 146 differentially expressed genes between the two subtypes, which were validated in an independent cohort. Pathway analysis demonstrated enrichment of inflammation-related and AKT/KRAS-associated signaling pathways in the large duct type. Mutation analysis showed that KRAS and PIK3CA mutations were more frequent in the large duct type, while IDH1/2 mutations and FGFR2 fusions were more common in the small duct type. CONCLUSIONS: Pathological subtypes of CCA exhibit distinct clinical outcomes and molecular characteristics. Classification based on pathological subtype provides a useful framework for understanding the clinical and molecular heterogeneity of CCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Keimyung University School of Medicine, Dongsan Medical Center, Daegu, Republic of Korea. Electronic address: ahnks@dsmc.or.kr.
- Bioinformatics & Medical informatics, Genomic Science Department, Ambry Genetics, Aliso Viejo, CA, USA.
- Department of Forensic Medicine, Kyungpook National University Schol of Medicine, Daegu, Republic of Korea.
- Hospital Pathology Associates, Minneapolis, MN, USA.
- Department of Pathology, Keimyung University Dongsan Medical Center, Daegu, Republic of Korea.
- Department of Surgery, Keimyung University School of Medicine, Dongsan Medical Center, Daegu, Republic of Korea.
Förderung
- Korea Ministry of Education
Zitieren
APA
Ahn, K. S., O'Brien, D., Kang, Y. N., Mounajjed, T., Lee, H. W., Kim, Y. H., Kim, T. S., Kim, M. J., Han, J. Y., Borad, M. J., & Roberts, L. R. (2026). Comprehensive Molecular-Clinical Profiling of Cholangiocarcinoma According to Pathologic Subtypes. HPB. https://doi.org/10.1016/j.hpb.2026.02.007
Vancouver
Ahn KS, O'Brien D, Kang YN, Mounajjed T, Lee HW, Kim YH, et al. Comprehensive Molecular-Clinical Profiling of Cholangiocarcinoma According to Pathologic Subtypes. HPB. 2026. doi:10.1016/j.hpb.2026.02.007
BibTeX
@article{Ahn2026,
author = {Ahn, Keun Soo and O'Brien, Daniel and Kang, Yoo Na and Mounajjed, Taofic and Lee, Hye Won and Kim, Yong Hoon and Kim, Tae-Seok and Kim, Min Jae and Han, Jin-Yi and Borad, Mitesh J and Roberts, Lewis R},
title = {Comprehensive Molecular-Clinical Profiling of Cholangiocarcinoma According to Pathologic Subtypes},
journal = {HPB},
year = {2026},
doi = {10.1016/j.hpb.2026.02.007}
}
EUVIMED